-
Lemtrada®
Lemtrada® (alemtuzumab) is a high-efficacy monoclonal antibody therapy used to treat relapsing forms of multiple sclerosis (MS) in patients who require a more targeted immune-based approach. At Singlepoint Healthcare, we provide a safe, supportive environment for Lemtrada® infusions, guiding each patient through the treatment experience with compassion, expertise, and personalized care.
How Lemtrada® Works
By selectively acting on specific immune cells that drive MS activity, Lemtrada® helps slow disease progression, reduce relapses, and preserve neurological function.
Lemtrada® works by targeting overactive immune cells (T and B lymphocytes) that mistakenly attack the brain and spinal cord, thereby reducing inflammation and limiting the progression of neurological damage.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | |
| Manufacturer | Genzyme |
| Administered by | Infusion |
| Frequency | 2 courses, 12 months apart: administered over 5 days for the first course and 3 for the second |
| Length of Infusion | 4 hours |
| FDA Approval(s) | Multiple Sclerosis (MS): Approved November 14, 2014 |